Effect of dienogest-containing oral contraceptives on lipid metabolism
article
OA: closed
CC0
⤵ 17 in-corpus citations
AI-generated summary
This study investigated the impact of dienogest-containing oral contraceptives on lipid metabolism in women.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
In a double-blind, controlled, randomized, four-arm, bicentric clinical study, the effect of four oral contraceptives (OCs) on lipid metabolism was investigated. Four groups composed of 25 volunteers each (mean age 26.1 +/- 4.5 years; body mass index 21.9 +/- 2.8 kg/m(2)) were treated for six cycles with monophasic combinations containing 21 tablets with either 30 microg ethinyl estradiol (EE) + 2 mg dienogest (DNG) (30 EE/DNG), 20 microg EE + 2 mg DNG (20 EE/DNG), 10 microg EE + 2 mg estradiol valerate (EV) + 2 mg DNG (EE/EV/DNG), or 20 microg EE + 100 microg levonorgestrel (LNG; EE/LNG). The study was completed by 91 women. Blood samples were taken by venipuncture after at least 12 h fasting on Days 21-26 of the control cycle and Days 18-21 of the first, third, and sixth treatment cycle. There were clear differences between the effects of EE/LNG and the formulations containing estrogens and DNG. Although EE/LNG did not change the triglycerides levels, a significant increase was observed during treatment with the DNG-containing preparations. Although EE/LNG significantly reduced HDL-CH and HDL(2)-CH, there was a nonsignificant increase with the DNG-containing OCs. No change was observed in the levels of HDL(3)-CH. A significant rise in apolipoprotein A1 occurred during intake with the three DNG-containing formulations, but not with EE/LNG. In contrast to the women treated with combinations of estrogens and DNG, apolipoprotein B rose significantly in the women in the EE/LNG group. Lipoprotein (a) was significantly reduced by 30 EE/DNG and EE/LNG and remained unaltered with 20 EE/DNG and EE/EV/DNG. Altogether, the changes in lipid metabolism caused by the DNG-containing formulations appeared to be more favorable than those observed with EE/LNG. In OCs with DNG, the EE dose does not seem to play a major role with respect to the effect on lipids.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (39)
- doi:10.1016/s0140-6736(99)80017-8 via openalex
- doi:10.1016/s0002-9378(16)32486-3 via openalex
- doi:10.1016/s0010-7824(98)00018-3 via openalex
- doi:10.1016/s0002-9378(85)80114-9 via openalex
- doi:10.1016/0002-9378(90)90584-t via openalex
- doi:10.1016/0010-7824(86)90065-x via openalex
- doi:10.1016/0010-7824(85)90006-x via openalex
- doi:10.1016/s0022-2275(20)39954-5 via openalex
- doi:10.1172/jci116437 via openalex
- doi:10.1021/bi00335a044 via openalex
- W2471626985 via openalex
- doi:10.1016/0002-9378(90)90583-s via openalex
- doi:10.1210/jcem-57-2-262 via openalex
- doi:10.1161/01.res.72.6.1300 via openalex
- doi:10.1016/0002-9378(93)90279-r via openalex
- doi:10.1016/s0002-9378(16)32485-1 via openalex
- doi:10.1111/j.1471-0528.1987.tb03151.x via openalex
- doi:10.1016/0002-8703(87)90629-6 via openalex
- doi:10.1016/0026-0495(84)90102-1 via openalex
- doi:10.1161/hc4801.099737 via openalex
- doi:10.1159/000184610 via openalex
- W378267022 via openalex
- doi:10.1186/cvm-2-3-107 via openalex
- doi:10.1016/0002-9378(83)90315-0 via openalex
- doi:10.1016/0010-7824(84)90079-9 via openalex
- doi:10.1111/j.1365-2265.1992.tb00959.x via openalex
- doi:10.1016/0021-9150(80)90251-8 via openalex
- doi:10.1016/s0010-7824(98)00074-2 via openalex
- doi:10.1016/0021-9150(85)90119-4 via openalex
- doi:10.1016/s0006-291x(81)80217-3 via openalex
- doi:10.3109/00016348709103647 via openalex
- doi:10.1016/0026-0495(83)90052-5 via openalex
- doi:10.1210/jcem-54-6-1113 via openalex
- doi:10.1016/s0002-9378(12)90408-1 via openalex
- doi:10.1016/s0010-7824(96)00182-5 via openalex
- doi:10.1016/0010-7824(87)90001-1 via openalex
- W4285719527 via openalex
- W6720533243 via openalex
- doi:10.1016/0010-7824(90)90066-5 via openalex
Cited by (15)
- Metabolic impact of combined hormonal contraceptives containing estradiol 2016
- Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review 2015
- Metabolic and Haemostatic Effects of Estradiol Valerate/Dienogest, a Novel Oral Contraceptive 2011
- Estradiol Valerate/Dienogest: A Novel Combined Oral Contraceptive 2011
- Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women 2011
- Ethinylestradiol/Dienogest in Oral Contraception 2010
- The use of newer progestins for contraception 2010
- A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis 2009
- Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use 2009
- Reprint of Pharmacological profile of progestins 2008
- Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate 2008
- A one-year randomized double-blind, multicentre study to evaluate the effects of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate and 2 mg dienogest on metabolism in postmenopausal women 2007
- New progestagens for contraceptive use 2005
- Pharmacological profile of progestins 2004
- Effect of four oral contraceptives on hemostatic parameters 2004
Source provenance
- openalex
- last seen: 2026-05-11T06:20:36.346967+00:00
- unpaywall
- last seen: 2026-09-12T07:21:10.926195+00:00
License: CC0
· commercial use OK